1 citations,
May 2017 in “InTech eBooks” The document concludes that alopecia areata is an unpredictable autoimmune hair loss condition with no cure, but various treatments exist that require personalized approaches.
[object Object] May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
March 2024 in “Current issues in molecular biology” Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.
September 2023 in “Drugs in context” Baricitinib is a promising treatment for alopecia areata.
August 2023 in “Dermatology and Therapy” Experts recommend personalized treatment plans for best outcomes in managing Alopecia Areata.
July 2023 in “Dermatology and therapy” People with alopecia areata may have a higher risk of blood clots.
[object Object] March 2022 in “Wound practice & research” New treatments for alopecia areata show promise, but standardized guidelines are needed.
September 2021 in “Journal of the Dermatology Nurses' Association” The convention discussed various skin conditions, treatments, and the importance of continuous learning in dermatology nursing.
88 citations,
August 2019 in “Frontiers in immunology” Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.
36 citations,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
25 citations,
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” Targeted cytokine treatments may help with alopecia areata, but more research is needed.
1 citations,
June 2023 in “Genes” Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.
1 citations,
May 2017 in “InTech eBooks” New treatments focusing on immune pathways show promise for stubborn hair loss.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
June 2024 in “Neuromuscular Disorders” Baricitinib successfully treated myasthenia gravis and alopecia in a patient.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
January 2024 in “Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica/Revista de la Asociacion Colombiana de Dermatologia y Cirugia Dermatologica” Baricitinib successfully treated severe hair loss.
3 citations,
February 2022 in “Rheumatology” Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.
January 2024 in “Case Reports in Dermatological Medicine” Baricitinib may effectively treat nail changes in alopecia areata.
33 citations,
January 2018 in “Blood” Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.
January 2019 in “Springer eBooks” Combination therapies might work better for some vitiligo patients, but results vary.
June 2020 in “Journal of Investigative Dermatology” The symposium highlighted the importance of genetics in understanding and treating complex skin diseases.
Baricitinib may effectively treat oral lichen planus.
8 citations,
October 2022 in “Dermatology practical & conceptual” Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
55 citations,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
5 citations,
June 2022 in “Frontiers in immunology” Increasing Treg cells in the skin does not cure hair loss from alopecia areata in mice.
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” HDAC inhibitors, like Vorinostat and Entinostat, can help regrow hair in alopecia areata.
2 citations,
March 2023 in “Frontiers in medicine” A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.
3 citations,
May 2023 in “International Journal of Molecular Sciences” A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.